Insights shared with Becker’s ASC Review by five GI leaders paint a picture of a specialty in transition. While colonoscopy remains central to colorectal cancer prevention, the business model built around it is under pressure from new screening options, shifting patient behavior, and changing payer strategies.
On the ground, demand remains strong — but it’s exposing operational bottlenecks that force practices to modernize and automate. At the same time, leaders are seeing real declines in screening colonoscopy volumes as stool-based and blood-based tests scale rapidly, often driven by payer-led outreach programs and consumer convenience.